NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Rewind Therapeutics

Rewind Therapeutics

Private
LeuvenHealthcare & Life Scienceshttps://rwdtx.com/

Last Round

Series A

Extension

Jan 25, 2023

Total Funding Raised

$21.6M

Company Overview

Rewind Therapeutics is a biotechnology company that develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from diseases such as multiple sclerosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyregenerative medicineremyelinationsmall moleculedrug discoverymultiple sclerosisdemyelinating diseasebiotech startupclinical-stage biotechtherapeutic candidateGPR17 antagonistdrug pipelinebiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rewind Therapeutics Comparables

Compare Rewind Therapeutics with similar companies based on industry and business-model similarity.

Rewind Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Convelo Therapeutics
87%
Progentos Therapeutics
86%
Find Therapeutics
86%

Rewind Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJan 25, 2023
GrantAug 2, 2019
Series AJan 4, 2018

Key People

Founding team and executive leadership

Anja Harmeier

Chief Executive Officer

Executive Team

Rewind Therapeutics Investors

Notable investors and investment history

Rewind Therapeutics investors
InvestorRounds
M VenturesSeries A Extension
Centre for Drug Design and DiscoverySeries A Extension, Series A
VLAIOGrant
PMVSeries A Extension, Series A
Boehringer Ingelheim Venture FundSeries A Extension, Series A
Sunstone Life Science VenturesSeries A Extension
M VenturesSeries A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 2, 2019

    $3.2M grant received from VLAIO.

Rewind Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Rewind Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Rewind Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLeuven
Employee Range14
Year Founded2017
Last FundingJan 25, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.